Longevity Medicine: Separating Evidence from Hype
Longevity Medicine: Separating Evidence from Hype
Life expectancy in Singapore is among the highest on earth. But we spend roughly the last decade of it in poor health. The interesting question was never how long you live. It’s how long you stay well.
What is longevity medicine actually trying to do?
Close the gap between lifespan — how long you live — and healthspan, how long you live well. In Singapore that gap runs to around a decade of dependency, illness and lost function at the end.
Nobody wants extra years in that decade. Everyone wants extra years in the other one.
It’s worth being straight about where this field is: it is early, heavily funded, and moving quickly — and that combination reliably produces both real advances and a great deal of expensive nonsense, often side by side in the same clinic. Local provision is still limited and offerings tend to be narrow, which is part of why people look abroad. It’s also why the ability to tell the two apart is currently the most valuable thing a patient can have.
Can you measure "biological age"?
Sort of, and the honest answer is more interesting than the marketing.
The idea: two 55-year-olds can be in wildly different physiological condition. Biological age tries to measure the condition rather than the birthday.
Epigenetic clocks are the headline method — analysing chemical marks on your DNA that change predictably with age. The newer ones are genuinely clever. Rather than estimating accumulated age, some estimate pace of ageing. If earlier clocks were an odometer, these are a speedometer, which is far more actionable.
The problems, which rarely make it into the sales page:
- The most technically sophisticated clocks turn out to be biologically fragile — results shift with recent meals, stress and pollution exposure. Day-to-day variation can easily be misread as your intervention working.
- Researchers running these tests recommend using several clocks at once, because a single result is unreliable enough to produce false positives.
- Accuracy varies by ethnicity, with documented bias against non-White populations. That matters here more than in most markets.
- Almost none of it has been shown to change hard outcomes when acted upon.
A fair verdict: interesting, improving, and not yet a basis for major decisions. If the number motivates you to sleep and train better, that’s a real benefit. Just don’t pay a lot for it, and don’t retest monthly expecting signal.
Meanwhile, the boring measures outperform it. Grip strength, VO₂ max, walking speed, body composition, blood pressure, ApoB, fasting insulin and HbA1c predict how you’ll age with better evidence than any commercial clock — and most are cheap.
What about wearables and new biomarkers?
A space genuinely worth watching, with the usual caveat that the marketing is running ahead of the validation.
Continuous glucose monitoring in people without diabetes is popular and the evidence for it is thin — most glucose “spikes” in healthy people are normal physiology, not damage. It can be a useful short-term education tool. It is not a diagnostic.
Sleep and recovery tracking is more defensible. Consumer devices estimate sleep stages imprecisely, but they track duration and consistency reasonably well, and those are the variables that matter most.
Heart rate variability is real physiology, highly individual, and best read as a personal trend rather than compared to anyone else.
Emerging blood markers — multi-cancer early detection tests, proteomic and metabolomic panels, organ-specific ageing markers — are the genuinely interesting frontier. Several will likely become standard within a decade. Most are not there yet, and early adopters are paying to be part of the validation process rather than benefiting from it.
And the frontier — peptides, stem cells, IV therapy?
This is the part everyone actually wants to ask about, so let’s take it seriously.
One thing to establish up front: these therapies are not yet regulated for general longevity use in Singapore, and are currently offered at selected centres overseas. That’s a statement about where the regulatory curve is, not a verdict on the science — early-stage adoption of any genuinely new technology looks exactly like this, everywhere, every time.
Here’s what each is reaching for, and where the evidence actually stands.
Peptides. Short chains of amino acids that act as precise signalling molecules — telling tissue to repair, or the pituitary to release growth hormone, or inflammation to settle. Some are long-established approved medicines. The ones generating excitement in longevity circles target tissue repair, body composition and recovery, and the underlying research is legitimately interesting. What’s missing is long-term human outcome data, and the retail market has significant variation in purity and sourcing. Real science, early evidence, uneven supply chain.
Stem cell therapies. The most ambitious idea on the list: cells that can become other cells, deployed to repair what age has degraded. Already approved and routine for specific conditions — certain blood cancers, some tissue reconstruction. For joint regeneration and general rejuvenation, the trials are running and some early signals are encouraging, but the evidence isn’t yet at the point where any regulator has approved the broader claims. The most exciting idea in the field, and the furthest from proof.
IV nutrient therapy. Delivers nutrients directly into the bloodstream, bypassing gut absorption entirely. There are clear medical indications where this is unambiguously the right thing to do. For general wellness in people whose levels are already normal, the honest position is that the surplus is largely excreted — the physiology is not in dispute. In Singapore, IV therapy sits within licensed healthcare institutions.
If you’re weighing up treatment overseas, four questions worth answering before you book: What human evidence exists for this specific indication, and where is it published? Is it approved anywhere for that use? Who handles a complication once you’ve flown home? And who reads the follow-up?
The fair summary: some of this will prove out and become standard within a decade. Some won’t. Right now the field genuinely cannot tell you which is which — and that’s worth knowing before you spend, not after. We’re happy to talk through where any specific therapy sits on that curve.
Our clinical insight
Living longer is becoming easier. Staying healthier for longer is the real challenge.
The uncomfortable truth about longevity medicine is that the interventions with the strongest evidence are the least exciting ones — building muscle, raising cardiovascular fitness, sleeping properly, controlling blood pressure and blood sugar, not smoking, staying socially connected. They are available to everyone and largely free.
That doesn’t make the frontier worthless. Some of it will prove out. But the sequencing matters: get the foundations measured and moving first, then consider the frontier — rather than buying an epigenetic clock while your grip strength, VO₂ max and ApoB have never once been measured.
The goal isn’t a lower number on a biological age report. It’s carrying your own luggage at 75.
What a serious baseline actually includes
The better longevity assessments now on the market — including those offered locally — tend to converge on roughly the same domains, which is reassuring:
- Cardiorespiratory fitness — VO₂ max or a submaximal equivalent. One of the strongest single predictors of all-cause mortality there is.
- Body composition — muscle mass, fat distribution, visceral fat, bone density.
- Muscular strength — grip strength, and functional measures.
- Respiratory function — spirometry.
- Metabolic and cardiac biomarkers — beyond the standard panel: ApoB rather than just LDL, lipoprotein(a) once in a lifetime, fasting insulin and HOMA-IR, hs-CRP, HbA1c, liver and kidney function, thyroid, vitamin D, iron studies, and sex hormones where relevant.
- Cognitive and mental health — baseline cognitive testing, sleep quality, mood.
What’s worth adding, on the right person: a coronary calcium score, which converts an abstract cardiovascular risk percentage into a picture of whether plaque is actually there.
What’s usually not worth it: broad tumour marker panels in people without symptoms or risk factors. They produce far more false alarms and unnecessary follow-up than they do early diagnoses.
🧭 The Healthspan Self-Audit
Twelve questions across the things that actually predict how you'll age. You won't get a score out of a hundred — you'll get your weakest link, which is where the return is highest.
Answer honestly rather than aspirationally. The point is to find the gap, not to score well.
Where to start
Where these six domains come from
Do any of the hyped supplements work?
Taking the four that dominate the conversation, honestly.
NMN and nicotinamide riboside (NAD⁺ precursors). The theory is sound: NAD⁺ declines with age and is central to cellular energy. Supplementation does raise NAD⁺ levels in humans — that part is established. Human trials show some improvement in markers like arterial stiffness and insulin sensitivity in specific groups. What hasn’t been shown is any effect on how long or how well people live. Safety looks good. Verdict: plausible mechanism, modest human data, heavily oversold.
Urolithin A. Derived from pomegranate metabolism, acting on mitochondrial quality control. Of the popular longevity supplements this has arguably the most credible human evidence, with randomised trials showing improvements in muscle endurance and mitochondrial markers. Effects are real but modest. Verdict: the best-evidenced of the fashionable options — which is a lower bar than it sounds.
Rapamycin. The most scientifically serious item on this list, and the most misused. It reliably extends lifespan in animals — one of very few interventions that does. But it’s an immunosuppressant, with real risks: infections, raised lipids, impaired wound healing. Human longevity trials are running; results aren’t in. Verdict: genuinely promising, genuinely a drug, and off-label use for longevity is experimental medicine. Anyone offering it should be saying that explicitly.
Taurine. A 2023 paper showing lifespan extension in mice generated enormous excitement. A key human correlation subsequently failed to replicate, which cooled things considerably. Verdict: cheap, safe, unproven. A good example of how fast a longevity headline can outrun its evidence.
The pattern across all of them: strong mechanism, encouraging animal data, thin human outcome data, confident marketing. None has been shown to extend human lifespan. Meanwhile the interventions that unquestionably do — not smoking, resistance training, cardiovascular fitness, sleep, blood pressure control, treating cholesterol and blood sugar — are unglamorous, cheap, and widely neglected by people spending heavily on supplements.
⚖️ The Evidence Grader
Popular longevity interventions and tests, graded on strength of human evidence. Filter to "strong" and see how short the list gets. That's the useful part.
Grades reflect Cresta Medical's reading of the human evidence at the time of writing — an editorial judgement, not a formal systematic appraisal. This field moves quickly and these ratings are reviewed annually. Nothing here is a recommendation for or against any specific product. Supplements can interact with prescribed medicines; check with your doctor.
Start with what's measurable
A healthspan baseline covers the things with genuine predictive value — cardiorespiratory fitness, strength, body composition, and an extended metabolic and cardiac panel — and gives you a number to track against.
These assessments sit across several providers. What a consultation does is work out which of them you actually need, arrange them, and then read the results together as one picture — including the frontier options, if that’s where your interest lies.
Cresta Medical · 10 Chai Chee Road, #01-01, Singapore 467010
Make your health a priority
Schedule an in-clinic appointment, or speak with Dr Alexis Wong and our care team online — whichever works best for you.